In their sights Aug 20, 2008
Earlier this year, for example, Sills Cummis represented Florham Park-based Bradley Pharmaceuticals in a deal where Nycomed, a Danish subsidiary of a Swiss company, acquired it for $300 million. Crane watched American companies drop out, one after the other, until Nycomed emerged as the lone suitor. (NJ.com -- Times)
Drug vets launch new firm May 13, 2008
When Bradley Pharmaceuticals founder Daniel Glassman tried to take the company private last year, he set in motion the law of unintended consequences. The directors of the specialty pharmaceuticals business, based in Fairfield, began actively shopping the business. (NJ.com -- Times)
QED International Associates Announces Changes to the HealthShares(TM) Dermatology and Wound Care Index Feb 22, 2008
NEW YORK, Feb. 21 /PRNewswire/ -- QED International Associates, Inc., administrator for the HealthShares(TM) Indexes, a series of 20 underlying indexes for the HealthShares(TM) Exchange-Traded Funds, today announced that effective at the opening of trading on Tuesday February 26, 2008, KV Pharmaceutical Co. (NYSE: KV.A) will replace Bradley Pharmaceuticals, Inc. (NYSE: ) in the HealthShares(TM) Dermatology and Wound Care Index. Bradley is being acquired by Nycomed US Inc., a subsidiary of... (PR Newswire)
Standard & Poor's Announces Change to U.S. Index Feb 15, 2008
NEW YORK, Feb. 14 /PRNewswire/ -- National Penn Bancshares Inc. (NASD: NPBC) will replace Bradley Pharmaceuticals Inc. (NYSE: ) in the SlCap 600 after the close of trading on Thursday, February 21, 2008. BDY is being acquired in a deal expected to close on or about that date, pending final approvals. (PR Newswire)
Bradley Pharmaceuticals Announces Filing of Definitive Proxy Statement for Special Meeting of Stockholders to Approve Merger With Nycomed Jan 18, 2008
FAIRFIELD, N.J., Jan. 17 /PRNewswire-FirstCall/ -- Bradley Pharmaceuticals, Inc. (NYSE: ) announced today that it has filed a definitive proxy statement with the Securities and Exchange Commission for a special meeting of stockholders to be held on February 21, 2008 at 9:30 a.m., Eastern Time at the offices of Morrison ter LLP, 1290 Avenue of the Americas, New York, NY 10104 for the purpose of voting on a proposal to approve the merger agreement with Nycomed US Inc., a subsidiary of Nycomed... (PR Newswire)
UPDATE 1-Nycomed to buy Bradley Pharma for $346 mln Oct 31, 2007
COPENHAGEN, Oct 30 (Reuters) - Privately-owned Danish drug maker Nycomed said on Tuesday it would buy Bradley Pharmaceuticals Inc. (BDY.N: , , ) for $20 per share, or $346 million, and delist it. The offer price represents a 25 percent premium to the specialty pharmaceutical company's closing price of $16. (Reuters)
Shire selling dermatology product portfolio, sources say Oct 3, 2007
Potential buyers for the asset include Swedens Meda, US-listed Bradley Pharmaceuticals (which owns the US rights to Solaraze), Belgium based Omega and several generic players such as Stada and Actavis would be interested, sources said. The Shire business makes about USD 50m in sales and is approximately 70% focused on the UK, according to one banking source. (FT.com -- Markets)
HealthShares(TM) Announces Quarterly Rebalancing of HealthShares(TM) Indexes Sep 18, 2007
5 Bradley Pharmaceuticals BDY 387550395. 1 Mentor Corp. MNT 144527406. (PR Newswire)
For a low-dose hormone, take your pick Aug 30, 2007
"We assume the lower doses are going to be safer, but we don't really have any data that has examined that," said Dr. Michelle Warren, founder and medical director of the Center for Menopause, Hormonal Disorders and Women's Health at Columbia University Medical Center and a consultant for Bradley Pharmaceuticals, the maker of Elestrin. Many women seeking natural remedies have turned to compounding pharmacies, druggists who promise so-called bioidentical hormones that are chemically synthesized... (International Herald Tribune)
Indian shares rally as latest US economic data instils faith Aug 27, 2007
20 rupees on reports it had joined the fray to buy US-based Bradley Pharmaceuticals Inc, to boost its presence in the dermatology segment. Punjab Chemicals Protection Ltd rose 5. (Forbes)
Noble Financial TWO DOUBLE-O-SEVEN Equity Conference Presenter Profiles Aug 18, 2007
BioSante's lead products include Elestrin(TM) (estradiol gel) developed through FDA approval by BioSante indicated for the treatment of moderate-to-severe vasomotor symptoms associated with menopause, marketed in the U.S. by Bradley Pharmaceuticals, Inc., BioSante's licensee, and LibiGel(R) (transdermal testosterone gel) in Phase III development by BioSante for the treatment of female sexual dysfunction (FSD). Also in development is Bio-T-Gel(TM), a testosterone gel for male hypogonadism, and an... (Yahoo! Wire -- Entertainment News)
Patches gain favor for hormone treatment Aug 17, 2007
Bradley Pharmaceuticals Inc. of Fairfield, N.J., has gambled $10 million on the shift ... Transdermal treatments are applied to the skin rather than taken orally, explained Bradley Pharmaceuticals Chief Executive Daniel Glassman in an interview Tuesday ... Bradley Pharmaceuticals agreed in November to pay Chicago-based BioSante Pharmaceuticals Inc., which developed Elestrin, $10 million to license and market the treatment in the United States. (Atlanta Journal-Constitution)
Bradley Pharmaceuticals Special Committee Receives Non-binding Preliminary Bids Aug 10, 2007
FAIRFIELD, N.J., Aug. 9 /PRNewswire-FirstCall/ -- The independent Special Committee of the Board of Directors of Bradley Pharmaceuticals, Inc. (NYSE: ) today announced that it has received preliminary bids for a possible sale of the Company in connection with its previously announced consideration of strategic alternatives ... Other Information: About Bradley Pharmaceuticals, Inc. Bradley Pharmaceuticals, Inc. was founded in 1985 as a specialty pharmaceutical company and markets to niche... (PR Newswire)
Takeover Doubts, Mortgage REIT Calls, Securitas Slump: Timshel Aug 8, 2007
The current list includes 10 newer entrants: Affiliated Computer Services Inc., Bradley Pharmaceuticals Inc., CKX Inc., Cumulus Media Inc., Horizon Offshore Inc., Huntsman Corp., PHH Corp., Riviera Holdings Corp., SLM Corp. and U.S. Xpress Enterprises Inc.. Except for Horizon Offshore, all those companies are the subject of buyouts. (Bloomberg -- Columnists)
Bid Is Tonic For Bradley Pharma's Stock May 30, 2007
Bradley Pharmaceuticals' founder and chief executive wants to take his company private, but he may have inadvertently put it into play on Tuesday with a $352 ... Bradley Pharmaceuticals (nyse: - - ) also has three patented drugs: Solaraze, a skin cream that treats actinic keratoses, dry, scaly skin patches caused by exposure to ultra-violet light; Elestrin, a gel that treats hot flashes; and Veregen, an herbal ointment made from green tea that treats geniotal warts. (Forbes -- Markets)
The World's Most Expensive Mutual Fund May 30, 2007
The Frontier Micro Cap fund seeks to invest in companies with less than $400 million in market capitalization, including holdings such as Pressure BioSciences (Nasdaq: PBIO), LJ International (Nasdaq: JADE), and Bradley Pharmaceuticals (NYSE: BDY). advertisement. (MSNBC -- Business)
Stocks to Watch Jan 3, 2007
-based insurance broker admitted no wrongdoing, but said in a statement that "it chose to conclude its involvement, rather than prolong what could be a costly and burdensome lawsuit." The company said it will take a pretax charge of $5 million to $10 million in its fourth quarter to increase its reserve for the costs to be incurred to conclude the settlement and to "resolve other regulatory and civil litigation matters Bradley Pharmaceuticals Inc. () shares dropped 14 percent Friday after the... (Fox News)
